SPARC gets orphan drug designation from USFDA for novel kinase inhibitor

The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 2 lakh people in the US, Sun Pharma Advanced Research Company (SPARC) said in a filing to BSE.

Original source:

Related Posts